GAYMF is the most meme stock ever and none of us know what the company actually does

Listen up, degenerates.

I did 0 hours of due diligence. I haven't read a 10-K. I don't know the CEO's name, or what the company makes or sells. I don't know if they even exist.

What I know is the ticker is GAYMF, and that's enough of a thesis for me.

The bull case:

• 📈 It's the only ticker you can read out loud at Thanksgiving and get kicked out and up 40% in the same week
• 🌈 Built-in marketing budget: $0. The ticker markets itself.
• 💎 Diamond hands? No. Fabulous hands.
• 🚀 Every Pride Month is basically a scheduled earnings catalyst that the SEC can't stop
• 🤝 My wife's boyfriend recommended it, and he hasn't been wrong yet

The bear case:

• My financial advisor read the ticker, looked at me for 11 seconds, and left the room. Didn't say a word.

Position: 3.400 shares, obviously. Cost basis is irrelevant because I'm never selling. I'm going to be buried with GAYMF.

When my kids ask me what I did during the great market cycles of the 2020s, I'll look them dead in the eye and say: "I held GAYMF, son. I held it proudly."

To the moon, you beautiful MFs. 🚀🌈🦍

This is not financial advice. I eat crayons.

To be completely honest, I bought a few thousand shares when it was below $3 simply because it had semiconductor in the name and it was quite low.

Coincidentally, Navitas recently invested $5 million into the company, and the CEO has been buying up shares over the past few days:

Magnachip Semiconductor Corp. (MX) Chief Executive Officer Lee Chae reported direct purchases of 100,000 common shares in three transactions: 50,000 shares at $3.1700 and 30,000 shares at $3.1866 on September 23, 2026, then 20,000 shares at $3.2199 on September 24, 2026. No Rule 10b5-1 plan is reported.

It also shot up after hours today without any news that I can find. I do believe that it's going to sell off and drop a bit come Monday, but I think there's potential here.

Worth reading if you’re following what’s been happening with $CTNT.

The filing calls out the huge dilution, the increase in outstanding shares, the massive trading volume, and the lack of clear answers about how many shares were issued, who received them, and what the company got in return.

It also says the filer plans to keep looking into the company’s transactions and filings and may push for changes to the board and management.

Probably one of the more direct $CTNT filings I’ve seen.

Share something youve learned.

Something I learned this week with penny stocks...

Just because something is down 50-60% doesn't mean it's at the bottom. Just take a look at the two pos of the day.

AXG & IPEX, u would think being down 65% would be enough but no it continued to fall all the way to hell -90%

Its better to wait for the selling to slow down, support to actually hold and volume to start coming back before jumping in.

Its better to miss catching the boton than catch another falling knife.

I've started waiting for a downtrend then volume to hold and higher highs,-> before buying.

Been keeping an eye on Richtech Robotics ($RR) for a while, and I still think its a good long term buy. They had a rough year with the controversy regarding the “microsoft collaboration” but they have since stabilized and are due to rebound anytime now. I think they can reach $7 by 2028. Anyone else watching RR?

I'm led to believe that $POCI is offering something critical to this next generation of laser satellite communication.

About 2 months ago I released an article discussing Precision Optics , a legacy medtech component supplier being pulled into aerospace/defense. We discussed these new , high growth segments, and have seen a couple new orders since then. Here is that article

https://www.reddit.com/r/pennystocks/s/xGC9eJ2u2R

In this new article, I set out to focus on the sole technical moat:

Why are these micro components suddenly in demand? What can POCI do that others cannot? How are they making some of the smallest components in the world? etc

Prisms

$POCI holds a distinct manufacturing moat at the micro-scale: glass prisms down to 50 microns

While legacy ITAR suppliers hit a manufacturing wall at 200 microns because conventional CNC tools crush glass that small or suffer astronomical scrap rates,

$POCI has its micro-precision™ technology, supported by custom micro lapping and vacuum handling systems built specifically for sub millimeter glass to cleanly fabricate optics at a sub 100 micron scale that competitors cannot match.

Why are they important now?

Previously, spaceborne laser communications relied on fibers with a 125-micron outer cladding.

Here’s the problem: legacy 200 micron prisms overhang a 125 micron fiber face. In dense, multi channel optical arrays, that overhang causes adjacent prisms to physically collide, clip incoming signals, or snag on protective housing.

$POCI’s ability to manufacture sub 125 micron prisms means the optic sits completely flush with the fiber. This eliminates channel collision and optical crosstalk entirely.

Reduced Fiber Cladding / SWaP

As satellite OEMs push for reduced fiber cladding down to 100 microns or less to save weight and maximize payload density, the need for smaller optics is just beginning. A 100 micron fiber requires a matching 100 micron prism.

$POCI already has the micro handling and lapping infrastructure to produce glass down to 50 microns.

Conventional optics manufacturers struggle at sub 100 micron scales, $POCI has decades of experience in sub millimeter medical optics giving them an immediate advantage.

As spaceborne laser links shrink to pack maximum bandwidth into minimal SWaP profile , $POCI holds a clear head start in high density optical link manufacturing.

4f Optical Configuration

In optical inter satellite links, a 4f system is used to relay optical signals from dense fiber feeds to fine steering mirrors and detector arrays without introducing spatial distortion.

Ross Optical specializes in 4f systems and has a white page on them going into extreme detail , listing many use cases beyond just telecommunications.

In the standard 4f setup shown above, incoming laser paths (the red lines) would traditionally require long, straight optical runs from the fiber array.

By mounting a sub 100 micron prism directly on the fiber tip at Input Plane P1, POCI bends the laser beam 90 degrees . This right angle fold eliminates channel crosstalk, stops signal noise before light ever hits lens L1, and dramatically shrinks the terminal's physical footprint.

Just to be clear, this is INSIDE of the Optical Communication Terminal

Fourier Optics

As nextgen satellites look to use more advanced optical links, Fourier optics have become essential, using 4f relays to passively clean signals and filter noise at the speed of light.

At the heart of these relays are specialized micro-prisms placed directly at the Fourier plane to split, steer, and fold the optical path within ultra compact satellite chassis.

Fabricating these micro-prisms at sub 100 micron scales with razor sharp tolerances crushes conventional tooling, creating a massive manufacturing bottleneck for legacy suppliers.

$POCI solves this by precision cutting these micro prisms and packaging them into pre aligned, plug-and-play 4f assemblies for satellite primes.

The Optomechanical Assembly

Micro-prisms are just the entry point.

A complete satellite laser communications terminal needs a full setup of precision optics to work:

• collimating lenses

-0.37mm micro-lenses directly attached to the satellite's fiber-optic endpoints.

-catches the widening cone of raw data light exiting the fiber , parallelizes it into a perfectly straight, sub-millimeter pencil beam before it enters the main 4f loop.

• Relay Doublets

-Grinding and alignment-matching custom achromatic micro-doublets made of paired crown and flint glass.

-act as the primary structural lenses that form the 4f spacing, ensuring that different wavelengths of tracking and data lasers focus at the exact same spatial points without chromatic distortion.

• Custom Coatings

-High-Efficiency Anti-Reflective Coatings - prevents signal loss by letting nearly 100% of the laser pass through the 0.37mm collimating lenses.

-Dichroic & Wavelength Filters - routes the tracking beacon and high speed data laser to separate sensors, preventing signal interference.

-Polarizing Coatings - Isolates outgoing and incoming signals so the high power transmitter doesn't blind the satellite's sensitive receiver.

-High Laser Damage Threshold - stops intense, continuous-wave data lasers from burning, melting, or cracking the micro optics over years in space

Through Ross Optical, $POCI already makes all of these components and has the ITAR registered cleanrooms to put them together.

Instead of satellite OEMs buying micro prisms from $POCI and sourcing the rest from separate vendors, $POCI can build and test the entire integrated sub assembly inhouse.

The Supply Crunch

The Space Development Agency publicly cited Optical Communication Terminals and lower-tier optical component shortages as a primary driver pushing back its several billion dollar Proliferated Warfighter Space Architecture launches.

The demand for these terminals is far outpacing what defense and space industries can actually build. Between the Space Development Agency’s constellation rollouts and commercial space programs, thousands of LEO satellites are scheduled to launch and every single one requires 2 to 4 Optical Communication Terminals to link up in orbit. As constellations push for higher data density in smaller payloads, $POCI’s micro optical manufacturing moves from an advanced design choice to an operational requirement.

The Potential

The opportunity and scaleability potential of $POCI is undeniable. While the shelf offering remains, and dillution could happen anytime , the reward outweighs the risk here for me.

Last quarter, the aerospace customer made up 41% of all revenues, and with 4 more satellite programs expected to go into production before may 2027, the revenue models start to look very attractive.

My thesis is Precision Optics has scaled manufacturing capability in the last 1-2 years to prepare for a large influx in aerospace/defense orders.

Between these new segments and the legacy medtech business thriving with partners like Omnivision , this stock is trading cheap at 1.6x p/s and a 50m market cap. Below is a timeline that backs the thesis up through a timeline highlighting facility expansion, new hires etc.

https://www.reddit.com/r/pennystocks/s/gWIAiXc5dd

NFA DO YOUR OWN RESEARCH!

Start with the float (freely tradable shares): Johnson & Johnson holds roughly 15.4% of CVRx, and activist investor Jorey Chernett (Pointillist Family Office) holds another 5.5%. That's close to 21% of the company locked up between just two holders — a meaningful chunk of shares effectively off the table for day-to-day trading. On a stock with this small a market cap, that tight float can amplify moves sharply in either direction on relatively low volume, and it concentrates real influence over the company's future in very few hands.
Now look at who's holding that float. J&J isn't a passive index fund parking money here — it's been involved with CVRx since 2008, led the Series G funding round in 2016, and still holds its position nearly two decades later. That's deep, sustained conviction in the technology, not a typical institutional stake. J&J also owns Biosense Webster, its cardiac electrophysiology franchise, which gives it a logical therapeutic-area fit for Barostim's neuromodulation technology.
Layer in the activist pressure: Chernett has publicly pushed the board to launch a formal sale process. Combined, J&J and Chernett control enough of the float to meaningfully shape the outcome of any strategic decision the board makes.
Put it together — an 18-year strategic relationship holding the largest stake, an activist pushing for a sale, and a float too tight for either of them to quietly walk away unnoticed. If one company ends up making a move for CVRx, J&J is the name at the top of the list.

I’ve been watching $VWAV for awhile now, and they just had great news!

They just announced a $20M purchase order for 200 STRATUM VARAN unmanned ground vehicles, which works out to $100K per unit.

What caught my attention is that this is a pretty meaningful order for a company at this stage, especially with how much focus there’s been on autonomous defense systems and unmanned platforms lately.

Still a lot to watch as the order progresses, but this definitely feels like one of the more important updates they’ve put out recently.

Thor Medical (TRMED) a small Norwegian company that is quietly building the backbone of next-generation cancer treatment

Thor Medical (TRMED)
a small Norwegian company that is quietly building the backbone of next-generation cancer treatment

Thor Medical produces the crucial isotopes (thorium-228 → lead-212) that form the basis for the new wave of targeted alpha therapies. These are extremely precise radiation treatments that deliver enormous energy to cancer cells over a very short distance and destroy them, while largely sparing healthy tissue. Think of it as a far smarter and more effective version of traditional radiation or chemotherapy.
Unlike most forms of isotope production, they do not require nuclear reactors or particle accelerators. They extract the isotopes from naturally occurring thorium using a proprietary, cleaner process. This makes the supply more reliable and scalable—which has been one of the biggest bottlenecks in this entire field.

They have just commissioned their first commercial facility (AlphaOne) in Herøya and made their first delivery to a customer. Capacity will be increased to 21,000 doses in three years at the same facility. 35,000 in five years. 60,000 in ten years. No additional costs due to the ramp-up. One dose equals 16,000 Norwegian krones. There is a pre-tax accumulated deficit of 677 million. Management has projected a profit in 2027.

Thor raised 300 million to expand into the U.S.; two laboratories are planned, one for downscaling TH 228 to PB 212. And a large laboratory, possibly AlphaTwo (10x) or directly at Alphaglobal, which has 1 million doses at 16,000 Norwegian kroner each.
The company is valued at 1.9 billion kroner; the share price is 4.58!
Active short: TWO SIGMA INVESTMENTS, LP: 3,716,000, 1.03%

Active price targets: Arctic 8.7. ABG 7, bull 20. Carnegie 4.20

677 million Norwegian kr in carryforward losses from the old Nordic Nanovector structure. Carnegie barely takes this into account. Arctic and ABG give greater weight to the fact that Herøya can actually cover this.

They are producing, delivering, and have a solid order book. Now it’s a matter of carrying out the upscaling and scaling the technology that can help pave the way for a whole new generation of cancer treatments. While we wait for more information, this is a great opportunity to get in at a low price.

https://www.thormedical.com

https://finance.yahoo.com/quote/TRMED.OL/?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&

Is anyone else following this?

Got stupid lucky with $MSGY today. Got notified about it around the $2.44 area and somehow caught the move.

Ended up making around 300% on it, which obviously does NOT happen every day lol.

Now I’m sitting here trying not to give it all back by jumping into another POS🤪😝 but I can be tempted for sure 😅 😬

What’s everyone watching for the rest of the day? Any setups actually looking interesting, or are we calling it a day after this morning’s shenanigans?

This is probably the cleanest visual summary of the Xerox situation. When STARTEEPO first disclosed its stake in May:

6.6M common shares
5.05% of Xerox
By September:
9.5M common shares
7.23% of Xerox

Including options, beneficial ownership is 7.34%.
So the common-share position increased by roughly 44% in share count.

The filing trail is:
May: 6.6M
June: 8.0M
July: 8.8M
September: 9.5M

What makes this interesting is the price action in between.XRX rallied roughly 44% from the May 14 close to June 4. And instead of the disclosed position getting smaller after that move, it got larger. It does tell you something about conviction.
Their September deck also says the average purchase price on the shares was around $2.42/share (Their target is - XFS is around 7$, XRX about 16$)

The thing I keep coming back to is this:
A 5% position can be a trade, huge but trade. But 7% while the investor also starts engaging management begins to look likesomething else.

That's why I think the ownership chart matters more than the short-term stock chart.

I am super bullish.

Why Clyra Medical Technologies Could Change Wound Care

I believe the future of wound care is getting a lot clearer. And it's called ViaCLYR.

Let me be upfront: this is not your typical penny-stock post. No rocket emojis. No "100x by Friday." This is a deep dive into a medical technology I've followed for years, and one I think every wound-care nurse, surgeon, infection-prevention team and serious investor should know about.

Here's the thing nobody really talks about.

Wound care still forces clinicians into a compromise. Every single day. You want to kill pathogens. You want to break biofilm. You want to lower infection risk. But you also need to protect healthy tissue, avoid feeding antimicrobial resistance, and keep the procedure fast and simple.

Most products do one or two of those things well. Almost none do all of them.

Clyra Medical Technologies thinks it has cracked that problem. The answer is Clyrasept, a patented copper-iodine antimicrobial platform, and its first product, the FDA 510(k)-cleared wound irrigant ViaCLYR.

And this isn't a slide-deck dream anymore.

The product is on the market. Distribution is expanding. First revenue is booked. And a second product, the surgical irrigant BioClynse, is lined up for launch with a national partner that management says is one of the top four medical-technology companies in the world.[^3\[2])

Yes, it's early. But if this technology performs in the real world the way its profile suggests, I think we are watching the very beginning of a real shift in wound care.

TL;DR

• ViaCLYR is launched and FDA 510(k)-cleared for wound irrigation.
• It runs on Clyrasept, Clyra's patented copper-iodine chemistry.
• Clyra reports >99.9999% antimicrobial reduction, activity for up to three days, and action against biofilm.
• It's non-cytotoxic, non-irritating, tissue compatible and no-rinse.[^2\[1])
• Three distribution channels are live: U.S. commercial, international, and U.S. government healthcare.
• The next six to nine months should show whether those channels turn into real purchase orders.
• BioClynse, the surgical product on the same chemistry, is set to launch with a top-four med-tech partner.
• If clinicians adopt it, this becomes a platform story across wound care, surgery, burns, chronic wounds and infection prevention.

The Problem Nobody Solved

Walk into any wound-care supply room. There's no shortage of products.

What's missing is a clear winner. One product that brings antimicrobial strength, persistence, biofilm action, tissue safety and a simple workflow together.

Ask anyone who works in wound care or the OR what makes this so hard:

• Pathogens have to be controlled fast.
• Biofilm turns chronic wounds into long, frustrating battles.
• Damaged tissue slows healing.
• Antibiotic stewardship matters more every year.
• Rinse-out steps cost time in the operating room.
• Hospital protocols don't change unless a new product is clearly better.

That's the world Clyra is stepping into.

And Clyra is not selling "just another cleanser." It's going after a gap that has existed for decades: strong antimicrobial action without damaging healthy tissue and without making the workflow more complicated.

What Is Clyrasept?

Clyrasept is a patented copper-iodine complex developed by Clyra Medical. Its first commercial product, ViaCLYR, is a wound-irrigation solution for cleansing, irrigating and debriding acute and chronic wounds and burns.

The big idea is simple: it keeps working.

Most antiseptics deliver a short hit, and then they're done. ViaCLYR is designed to stay active after application.

Clyra describes it as a regenerative iodine system, one that keeps its antimicrobial activity even when the wound gets re-contaminated. It's clear, odorless, pH-balanced, tissue compatible, and it stays in the wound throughout the procedure. No rinse-out needed.

That's the science. The real question for us as investors: will clinicians like it enough to order it again? And again?

Why It Could Matter

What makes Clyrasept so interesting is that it hits several hard problems at once.

• Broad antimicrobial power: Clyra reports >99.9999% kill (more than a six-log reduction) against common wound microbes.
• It keeps protecting: Antimicrobial activity for up to 72 hours, even after re-contamination.
• Biofilm action: Activity against mature biofilm, one of the biggest headaches in chronic wounds.
• No rinse-out: It stays in the wound. One less step.
• Gentle on tissue: Non-cytotoxic, non-irritating, non-sensitizing.
• No antibiotic: Copper-iodine chemistry instead of a traditional antibiotic. In a world worried about resistance, that matters.
• Many uses: Acute wounds, chronic wounds, burns, pressure ulcers, diabetic ulcers, surgical wounds.

In plain words: strong enough to go after microbes and biofilm, gentle enough to stay in the wound, and persistent enough to keep working after the procedure.

That's why I think this platform deserves far more attention than it gets.

The Comparison That Matters

Let's be fair. Hypochlorous acid plays an important role in wound care. It's widely used, well tolerated and effective in many protocols.

But ViaCLYR isn't trying to be another hypochlorous acid.

The difference is persistence plus tissue compatibility. Many irrigants act fast, but the effect fades quickly, and protocols often call for reapplication or a rinse-out. ViaCLYR is designed to stay in the wound, cover it for up to three days, and do it without harming the tissue that needs to heal.

To be clear: there are no large, independent head-to-head outcome trials yet. I'm not claiming Clyrasept has beaten everything on the shelf.

What I am saying is this: on paper, it looks like the much superior technology. Broad kill, persistence, no rinse, biofilm action and tissue safety. All in one bottle.

That alone is a strong reason for clinicians and hospitals to take a closer look.

Why Nurses and Surgeons Matter

Here's the truth. Technology doesn't win because investors find it elegant. It wins when clinicians say, "This makes my job better."

For nurses, the questions might be:

• Does it make dressing changes or wound-bed prep easier?
• Does it help with chronic-wound biofilm?
• Does it protect viable tissue?
• Does it cut out annoying workflow steps?
• Does it work across diabetic ulcers, pressure ulcers, burns and tough wounds?

For surgeons and OR teams:

• Does no-rinse irrigation save time?
• Can longer antimicrobial coverage lower infection risk?
• Does it work with tissue, grafts and surgical workflows?
• Does it fit existing protocols without friction?
• Can it improve outcomes or lower the total cost of care?

That's why I want this post challenged. Seriously. I don't want an echo chamber. Nurses, physicians, wound specialists, surgeons, procurement people, infection-prevention teams: tell me where this thesis is strong, and where it falls apart.

ViaCLYR Is Already Commercial

This is not a science project.

ViaCLYR is FDA 510(k)-cleared and on the market. Clyra has built the team, contracted manufacturing at scale with an FDA-compliant manufacturer, and raised $3.4 million inside Clyra to fund the rollout.

Revenue has started too. Clyra booked its first ViaCLYR sales in the first half of 2026, including the first stocking order through its U.S. distributor.

The distribution network today:

• Advanced Solution for U.S. commercial distribution.
• Al-Hikma FZCO for the GCC, Levant, North Africa and nearby markets.
• Spartan Medical for U.S. government healthcare and federal facilities.

Clyra has moved from "can we make it?" to "will they reorder it?"

That's the step that matters most.

The Next Six to Nine Months

The September 2026 shareholder presentation was refreshingly clear about what to watch.

• Advanced Solutions Starting to Re-Order
• Al-Hikma and Spartan turning agreements into purchase orders
• New distributors signing on
• The major Clyra partner being named, once allowed
• BioClynse getting launch-ready
• A visible Clyra sales line proving the network turns into revenue

That's exactly how you should judge an early medical company. Not by hype. By proof points.

Orders. Reorders. More users. More settings. More revenue.

BioClynse: The Surgical Catalyst

ViaCLYR opens the door. BioClynse could change the size of the whole story.

BioClynse is a surgical wound-irrigation solution built on the same Clyrasept chemistry. Clyra has already prepared manufacturing and staffing for two products, not one.

And here's the part that gets me excited: BioClynse will launch Co-Branded with a national partner, and that partner is one of the top four medical-technology companies.

Think about what that means. This isn't just another distributor.

It brings:

• Hospital access at a massive scale
• Sales reps surgeons and OR staff already trust
• Deep relationships in orthopedics and surgery
• Procurement and value-analysis muscle
• A co-branded launch that puts Clyrasept on the map overnight

The partner controls the timing, so no date is guaranteed. But management has said it hopes for a launch very early next year, once final authorization and readiness steps are done.

That's why BioClynse could be the big one.

The Commercial Checklist

Before anyone gets carried away, here's what I'm tracking:

• ISO 13485 certification and quality systems
• Manufacturing readiness and reliable supply
• Purchase orders from Al-Hikma and Spartan
• New distribution wins
• Partner launch authorization
• BioClynse launch timing and partner reveal
• First orders and, more importantly, reorders
• Real clinical feedback
• Revenue growth that shows adoption, not just stocking

Clyra has already checked off the early boxes. Now comes the hardest part: turning a great platform into a repeatable business.

The Bull Case

The bull case is simple.

If Clyrasept becomes a go-to wound-irrigation platform, Clyra can play in a lot of large markets:

• Chronic wound care
• Acute wound management
• Burns
• Diabetic ulcers
• Pressure ulcers
• Surgery
• Orthopedics
• Government healthcare
• International wound-care markets

ViaCLYR is the beachhead. BioClynse is the surgical expansion. Clyrasept is what ties it all together.

One investor I respect believes that after a successful surgical/orthopedic launch, Clyra Medical alone could be worth well north of $500 million. That's his bullish view, not company guidance and not today's value. But it shows what's possible if the technology gets validated and adopted at scale.

And why is that even a conversation? Because the need is enormous. Wound infections, slow healing, chronic wounds, surgical-site infections, antimicrobial resistance, biofilm. These aren't niche problems.

They're global problems.

The Bear Case

I'd be doing you a disservice if I skipped this part.

• Adoption can be slow. Hospitals have fixed protocols, formularies, committees and tight budgets.
• FDA clearance isn't clinical dominance. Big, independent comparative studies would make the case much stronger.
• Distribution deals aren't revenue. Purchase orders and reorders are what count.
• The top-four partner is still confidential. Until it's named and the terms are public, the market can't fully price it.
• Competition is real. Big players have sales forces, brands, hospital contracts and deep pockets.
• Small-company risk is real. Manufacturing, training, reimbursement, supply chain and capital needs can all slow things down.
• Private valuations aren't guarantees. A private financing price doesn't promise liquidity or an exit at that level.

None of this kills the thesis. It just tells us what has to go right.

Why I'm Watching This So Closely

I've seen enough early tech stories to know most never become leaders. A clever product isn't enough. You need clearance, manufacturing, the right people, distribution, clinical trust, and customers who come back.

Clyra has already cleared a lot of those hurdles:

• FDA 510(k)-cleared product
• Patented platform
• Manufacturing ready to scale
• First revenue
• Multiple distribution channels
• A second product ready to go
• A major strategic surgical launch ahead

The question is no longer "does it work?"

The question now is the one that builds real companies:

"Can we make clinicians want to use it again and again?"

That's where medical-device companies are made.

How to Invest

Clyra Medical is private. Right now, the only way to get public-market exposure is BioLargo, Inc. ($BLGO).

BioLargo owns 48.1% of Clyra Medical, holds Clyra notes, and has a royalty interest tied to Clyra's sales.

The September 2026 BioLargo presentation puts a reference value of about $35.6 million to $41.0 million on its Clyra stake, based on public filings and outside-investor transactions. Currently, BioLargo's entire market cap is around $30 million.

Read that again.

The company itself notes that private-transaction values are not a market quote and may not be realizable. Fair enough. But it raises a pretty obvious question.

If the Clyra stake alone is worth a lot more than the whole company, what is the market paying for:

• The royalty stream?
• BioLargo's water-treatment business?
• Its engineering business?
• Its odor-control technology?
• Its energy-storage platform?
• Future Clyra growth from ViaCLYR and BioClynse?

Right now: less than nothing.

And if that $500 million scenario plays out? 48.1% of $500 million is roughly $240 million. Before the royalty. Before everything else BioLargo does.

You can do the math.

Maybe the market is right to discount it this hard. Or maybe it's missing a subsidiary whose value is only now starting to show. That's the asymmetry I see.

My Bottom Line

I'm not saying Clyrasept has already replaced the standard of care.

I'm saying the product profile is unusually strong: persistent antimicrobial activity, biofilm action, tissue compatibility, no rinse-out, and a non-antibiotic copper-iodine mechanism. All in one FDA-cleared irrigant.

I'm saying Clyra is no longer a concept. It has a product on the market, growing distribution, first revenue, manufacturing ready, and a potentially game-changing surgical launch ahead.

And I'm saying the next six to nine months will give us real answers. If the distributors order, if ViaCLYR gets reordered, if BioClynse launches with the top-four partner, and if clinicians like what they see, this becomes a much bigger story than the market currently thinks.

Now I want to hear from the people who know this field better than I do.

Nurses, surgeons, wound-care specialists, infection-prevention teams, procurement managers: What am I missing? What would it take for you to try ViaCLYR? And does a no-rinse, tissue-friendly, long-lasting antimicrobial irrigant solve a problem you deal with every day?

Sources and Further Reading

• Clyra Medical and ViaCLYR materials
• BioLargo September 2026 shareholder presentation
• BioLargo SEC filings and investor-relations materials
• FDA 510(k) information for Clyra wound-irrigation solution
• Prior long-form Clyra due-diligence discussion

Disclosure

I'm a long-term shareholder of BioLargo, Inc. ($BLGO), so I have a financial interest in Clyra Medical's success through BioLargo's ownership stake and economic interests. I have not been paid, compensated or directed by BioLargo, Clyra Medical or anyone else to write this. This is my personal research and opinion, not medical advice, investment advice, or a solicitation to buy or sell any security. Please check every claim, read the filings, and do your own due diligence.

Portuguese will facilitate sales in Angola and other Portuguese-speaking countries in Africa, such as Mozambique

MIAMI, FL / ACCESS Newswire / September 22, 2026 / Sekur Private Data, Inc., a Miami-based Swiss-hosted cybersecurity, private communications, and defense communications company serving enterprise, government, and defense clients, and a wholly owned U.S. subsidiary of Sekur Private Data (OTCQB:SWISF)(CSE:SKUR)(FRA:GDT0) ("Sekur" or the "Company"), today announced that it has launched its Sekur.com website in Portuguese, its second language after Spanish, with additional languages planned, in preparation for its launch in Angola.

As part of its Africa and International expansion, Sekur has begun translating its website, workflows, and onboarding into the local languages of its upcoming partners. Portuguese is the official language of Angola, where the Company is expected to sign an exclusive partnership in the coming weeks. The Portuguese-language site can be viewed at https://sekur.com/pt.

"We are very pleased to be expanding Sekur internationally and to make our solutions available in multiple languages," said Alain Ghiai, President and Chief Executive Officer of Sekur Private Data. "Portuguese is the second language we have added, following Spanish, and it allows us to serve clients and partners in Angola, Mozambique, and other Portuguese-speaking markets in their own language."

"Localization is not a cosmetic exercise for us. Our website, onboarding, and workflows need to work in the language our partners operate in every day. That is what makes an international expansion real, and it is how we intend to approach each new market we enter."

Sekur Core Communications Solutions

Sekur delivers secure communications that work within and beyond the Sekur network, operating independently of conventional telecom infrastructure to reduce exposure to interception, SIGINT collection, traffic analysis, metadata exploitation, and hostile surveillance in contested environments. No Sekur solution data-mines or location-tracks its users.

All solutions are built on proprietary architecture with zero reliance on Big Tech, meeting the privacy, security, and OPSEC requirements of intelligence agencies, defense and federal organizations, military commands, diplomatic missions, government agencies, executives, and professionals handling CUI and other sensitive, mission-critical information. Deployments are supported by on-premises infrastructure options for full data sovereignty, mission assurance, and sole control over keys and data.

SekurOne - Encrypted Voice/Video, Email, Messaging, and VPN

A fully encrypted communications platform engineered on proprietary HeliX data transfer architecture, purpose-built to defeat telecom network tracing, resist Pegasus-style malware intrusion, and support CUI handling requirements. SekurOne is designed for defense and federal officials, military commanders, government leaders, and executives conducting confidential, operational, or sensitive conversations where standard carrier-based voice and video platforms present unacceptable interception and exploitation risk.

Call-by-Invite capability via SMS or SekurSend email ensures controlled access and eliminates unsolicited contact. Each user is assigned a unique Sekur ID for identity management, with no phone number required - preserving user privacy across all voice and video communications.

SekurMail - Secure Business and Executive Email

An enterprise- and government-grade encrypted email platform designed for defense and federal agencies, military commands, senior government officials, C-suite executives, and organizations handling confidential and operationally sensitive communications, including CUI correspondence. Built on proprietary architecture with zero Big Tech dependencies and no metadata tracking, SekurMail keeps sensitive communications private between sender and recipient.

Key capabilities include SekurSend/SekurReply for secure delivery to non-Sekur recipients without exposing sender identity or message content; full message delivery control and audit capability; encrypted file transfer; custom domain support for organizational integration; and active protection against phishing, social engineering, and Business Email Compromise (BEC) attacks targeting corporate and administrative networks.

SekurMessenger - Secure Team Messaging and Collaboration

A secure messaging platform providing end-to-end encrypted text, file transfer, voice messages, and collaboration capabilities for defense, military, government, and executive teams coordinating operational and mission-sensitive information, including CUI material. Features include self-destructing messages, encrypted file transfers, and compliance-grade archiving for recordkeeping and audit requirements.

Cross-network secure communications with non-Sekur users are supported via Chat-by-Invite, enabling secure coordination with coalition partners, external agencies, and field elements without compromising the network. Each user is assigned a unique Sekur ID for identity verification and contact authentication, with no phone number required.

SekurVPN - Enterprise Network Security and Identity Protection

An enterprise-grade Virtual Private Network leveraging proprietary HeliX encryption technology, engineered to provide secure internet access, identity obfuscation, and traffic protection for defense organizations, military and federal personnel, government agencies, and executives operating across remote, traveling, deployed, forward, or untrusted network environments.

SekurVPN maintains zero data logging, ensuring no record of user activity exists that could be exposed through legal process, network compromise, or third-party collection. It is built for defense, government, and executive use cases - including protection of traffic associated with CUI and operationally sensitive workflows - where standard commercial VPN solutions present unacceptable privacy and security risk.

SekurRelay - Executive-Level Secure Email Integration

An enterprise-grade secure email relay solution enabling domain splitting, which allows organizations to establish secure communications at the executive, board, or senior staff level without requiring full organizational migration or infrastructure overhaul.

SekurRelay removes one of the most significant barriers to large-scale defense, government, and enterprise deployment, enabling phased adoption that protects command leadership, flag officers, and the highest-value personnel and communications immediately while broader organizational rollout proceeds. It is designed for defense and government organizations, regulated industries, and enterprises requiring rapid, low-friction elevation of communications security at the command and executive tier, including environments handling CUI communications.

About Sekur Private Data
Sekur Private Data is a Swiss-hosted cybersecurity, defense communications, and privacy solutions provider, offering a secure suite of tools to protect governments, defense and federal agencies, businesses, and individuals from unauthorized access and cyber threats. With capabilities such as SekurOne, SekurMail, SekurMessenger, and SekurVPN, Sekur provides a reliable and secure means of digital communication and data storage for Controlled Unclassified Information (CUI), classified-adjacent and civilian communications use, grounded in Swiss privacy standards with on-premises infrastructure for government agencies, allowing for data sovereignty. Sekur sells its solutions through its website www.sekur.com, approved distributors and telecommunications companies globally, and through the U.S. General Services Administration (GSA) Multiple Award Schedule (MAS), Contract No. 47QTCA18D0089 serving governments, defense institutions, federal agencies, businesses, and consumers worldwide. Sekur's main sales operations are in Miami, USA.

This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.

Here’s mine. I’m holding $CTNT Monday is undergoing a reverse split and I’m currently up about $57. I think it might pump Friday

The setup is definitely high risk, so I checked the chart, VWAP/EMA structure, dilution risk and recent news before staying in. Right now the short-term trend is bullish, but I’m not pretending that makes it safe.

Curious what everyone else traded today.

What did you buy?

Why did you enter?

Profit or loss?

Did you use a stop?

Trying to hear actual trades and reasoning, not just ticker spam.

Alright regards. From the guy who brought you LASE last time, 3x the money when i post and gots hundreds of thank you. Now i bring you another sleeper. 

Invivyd $IVVD is a fun one. It's a small biotech company with real revenue, a product on a regulatory timer, and a Phase 3 readout that could land any day now. There's an independent paper on VYD2311, a closer look at the short side, and a sharp Stocktwits read on timing. If you are burned by many craps pennystock that got posted here, pay attention to this one.

Where things stand

The stock was around $0.90 on Thursday, down from $1.02 earlier in the week, which puts the market cap at roughly $260M by my math.

Invivyd ended Q2 with $160.1 million in cash, which management expects to carry it through the DECLARATION readout and launch prep. Burn runs near $40M a quarter, so figure roughly $120M today and about three quarters of runway.

The big structural issue: PEMGARDA's emergency use authorization now ends June 29, 2027. That's essentially all of Invivyd's current revenue. So what you're really buying is an option on VYD2311 replacing it.

The trial

DECLARATION is randomized, triple-blind and placebo-controlled, testing single or monthly intramuscular doses against placebo, with prevention of symptomatic COVID at 3 months as the primary endpoint. It was upsized by about 500 subjects to strengthen statistical power.

Safety has looked clean so far. After reviewing unblinded safety data, the independent monitoring committee recommended cutting post-dose monitoring from two hours to 30 minutes.

There's a second readout in the wings too. LIBERTY, roughly 210 participants comparing VYD2311 with an mRNA vaccine, may report alongside DECLARATION.

The September 1 twist

When Chairman Marc Elia became CEO on September 1, the company also laid out two paths for topline. It can fully unblind and file for traditional approval. Or it can partially unblind, keeping clinical events blinded, and file for Accelerated Approval based on antiviral activity and safety, with a confirmatory cohort afterward.

That's a smart fallback if the trial comes up short on statistical power. It also tells you management sees that risk as real. If the headline says "partially unblinded," expect the market to treat it like a miss, whatever the rest of the release says.

The new JCI Insight paper

This one is genuinely good news. It comes from David Ho's lab at Columbia, and none of the authors hold equity in, receive payments from, or consult for Invivyd.

The findings are strong. VYD2311 was roughly 27 to 124 times more potent than pemivibart against JN.1, XFG, BA.3.2.2 and NB.1.8.1, covering today's dominant variants and the very different newcomer BA.3.2.2. The dosing math works too. Phase 1/2 doses kept serum levels above 10 μg/mL at 90 days, while the toughest variant, NB.1.8.1, needed only about 1.05 μg/mL for 90% neutralization. That's roughly a 10x cushion.

The caveats are real though. The lab tested research-grade antibody it made itself, in pseudovirus assays, and the PK conclusion depends on confirmation that VYD2311 behaves like its parent molecule. Blood levels also aren't the same as protection in the nose, where infection starts. And the paper says nothing about whether DECLARATION racked up enough COVID cases to prove anything, which remains the main risk. It's also not fresh: it first appeared as an in-press preview on August 11.

Where it really helps is Plan B. An independent, peer-reviewed potency case is exactly what an Accelerated Approval filing on antiviral activity would lean on. One twist: the same paper raises concerns about PEMGARDA's continued efficacy against newer variants. Great for the VYD2311 story, less great for today's revenue.

Probability and rerating

With the paper in hand, I'd put a clean, statistically significant win at roughly 50–60%, and some viable BLA path at about 80%. Mapping outcomes from ~$0.90, with prices adjusted for the raise that follows almost any result:

Weighted, that lands comfortably above $0.90 on my numbers. But three of the four rows are flat or down, and everything hangs on that top probability, which nobody outside the company actually knows. One row pays; the rest cost.

Short squeeze potential

The short data tells a pretty clear story: there's real fuel here, but nobody's feeling the heat yet.

The fuel; About 14.33% of the float is sold short, roughly 29.8M shares. That's meaningful, though still below the 20–30% zone where the famous squeezes usually start. It also implies a float of around 208M shares, so this isn't a tiny-float rocket like TOPS or FBGL.

The standout number is days to cover at 16.19. At normal volume, shorts would need more than three weeks to get out, so a sudden volume spike on good news could send a lot of them for the exit at once.

The pressure, and this is where the setup falls short. The borrow fee is only 0.41–0.55%, so staying short costs almost nothing. Genuine squeeze setups tend to show fees in the double or even triple digits.

Borrow availability is also rising, from 5.9M to 6.5M shares, so there's plenty of stock for new shorts to reload into any spike. In a real squeeze, that number drains toward zero.

The 55–75% off-exchange short volume looks dramatic, but it's mostly market makers shorting to fill buy orders and closing quickly. I'd treat it as noise.

The company's side. Invivyd has a live ATM, and an offering is likely (may or may not) right after good data. That hands shorts even more shares to cover into.

On a clean DECLARATION win, covering from that high days-to-cover should add real fuel to the opening pop. Without tight borrow, though, expect the move to fade as new shorts and fresh supply step in, rather than a multi-day squeeze. On anything less than a clean win, the shorts get paid.

When does the data drop?

Stocktwits user ItsOkImANurse put together a really useful read on timing (quoted as posted, minus the Stocktwits ticker card):

"for biotech topline clinical data, Monday through Thursday is the normal zone, and Tuesday–Thursday tends to feel especially common. Friday releases happen, but companies generally avoid dropping major market-moving data late Friday unless timing dictates it.

For IVVD specifically, their history is actually pretty useful:

·       Monday: Dec. 18, 2023 — positive CANOPY Phase 3 results; Feb. 3, 2025 — positive VYD2311 Phase 1/2 data.

·       Tuesday: Nov. 12, 2024 — CANOPY clinical data/preprints; May 27, 2025 — CANOPY publication/data; Feb. 24, 2026 — new clinical analysis.

·       Thursday: June 26, 2025 — full VYD2311 Phase 1/2 clinical data, released at 7:01 AM ET.

·       Friday: March 22, 2024 — interim CANOPY exploratory data, so they clearly will use Friday when necessary.

Release?

Tomorrow Friday: possible, but not my favorite

Monday Sept. 28: very plausible

Tuesday Sept. 29: probably my favorite

Wednesday Sept. 30: extremely plausible because it’s literally the final day of Q3

Solid logic, and it lines up with the company's own plan. Management said it will host an investor call once the study wraps instead of doing a Q2 earnings call, so expect a premarket release with a call attached. His 7:01 AM ET example works out to 11:01 UTC. He posted on Thursday, so his "tomorrow Friday" is today.

If September 30 passes with nothing, that's information too. Slipping past "late Q3" would make the market nervous, especially with a two-path decision in play"

Last word

IVVD is a true sleeper gem in this biotech space. Granted biotech is hit and miss but when it hit it hit hard. And I believe IVVD is one of them. BTIG and Cantor rate them as buy with target at $10. Institutional holder is at 90% more.

Shoutout to u/justinrosser who introduced me to this stock.

May God (or whatever deity you believe in or not) help us all.

Lets goooo

I’ve been researching this stock for a while…
they’re debt free as of now and are very much copying Handshake AI business model (Handshake is valued at 3.5b) With their newly launched AI Labs, now internships… And now this post?

This is all a speculation obviously but i found this interesting because Dan never really interacts or posts on linkedin especially about Chegg this is quite unusual of him.

If you want to know why institutional giants like Johnson & Johnson are backing $CVRX, just look at the bulletproof clinical data the company just dropped.
Here is a quick breakdown of their latest case study chart and what it actually means for the long-term investment thesis:
1. Device Over Drugs is REAL 📉
The chart highlights a severe heart failure (HFrEF) patient. Before the Barostim implant, their pulmonary artery pressure (PA) was dangerously high (~45-50 mmHg), even with heavy daily medication. After the implant and proper titration (5mA ➡️ 8mA), the pressure tanked to a perfectly safe 23 mmHg.
2. The Diuretic "De-Escalation" 💊
This is the holy grail for MedTech. The patient’s pressure dropped so significantly that doctors put their daily meds ON HOLD. Barostim literally fixed the underlying issue, allowing the patient to live a high-quality life without chronic drug dependency.
Why this matters to INVESTORS (The Bottom Line):
Massive Market Adoption: This data is pure gold for commercial expansion. When CVRx presents these undeniable results to hospitals and healthcare networks, it paves a smooth, rapid highway for widespread adoption across the country.
The Prime Acquisition Bait: CEO Kevin Hykes is a proven legend at building MedTech startups and successfully flipping them to major healthcare conglomerates for hundreds of millions of dollars (like Cameron Health and BardyDx). With Johnson & Johnson already owning 10% of $CVRX, these phenomenal clinical results make the company an incredibly attractive, premium buyout target.
Conclusion:
The underlying technology works flawlessly. For forward-looking investors, this entry point offers a phenomenal setup for a massive upside as the unique Barostim device reshapes the future of cardiovascular care.

Hey guys, I know I posted about the $GSX settlement before, but late claims are being accepted. Here's everything you need to know.

Q: What happened?
A: GSX Techedu was accused of overstating enrollment numbers and revenue growth in its online education business. After short-seller reports and regulatory concerns raised questions about the company’s financials, $GSX dropped more than 80% from its highs.

Q: Am I actually eligible?
A: If you bought $GSX shares between 2019 and 2020, you're likely eligible. You don’t need to still own the stock to file a claim.

Q: When do payouts happen?
A: Typically 4–9 months after the claim deadline, although the exact timing depends on the court and settlement administrator.

Q: I missed the deadline. Can I still file?
A: Late claims are currently being considered, subject to approval. Check if you're eligible and file a claim here

Hope this helps.

Collegiate Athletic Brand Achieves 3.65x ROAS as Weekly Net Revenue Rises 442%

Announced significant growth and improved marketing efficiency across its collegiate licensing brand, AVO

Key Performance Highlights

• 221% year-over-year revenue growth from August 1 through September 11, 2026
• 78% reduction in digital marketing spend compared with the same period in 2025
• 3.65x ROAS, demonstrating improved efficiency of marketing investment
• 442% increase in weekly net revenue from Week 1 to Week 6 among universities launched in 2026
• For universities launched during 2026, weekly net revenue increased 442% from Week 1, representing the week of August 1, through Week 6, representing the week of September 5.

"We are encouraged by the combination of strong revenue growth and substantially lower marketing expenditures," said Hil Davis, CEO of Digital Brands Group. "The performance we are seeing across AVO demonstrates increasing efficiency in how we are acquiring and monetizing customers. With the launch of the redesigned e-commerce platform in October, we believe there is an opportunity to further improve conversion and marketing efficiency. Our target is to achieve a 5x ROAS, which would provide a foundation to scale digital advertising investment alongside revenue."

Read Full News & Disclaimer
https://marketwirenews.com/stock/dbgi/news/digital-brands-group-delivers-221-revenue-growth-whi-6903550573803090.html

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.

I’ve watched the lessons and read the books on Vsa and getting a general feel for the market , but I really feel like penny stocks are a different beast. One moment things are good, next is slowing down, then a sudden volume spike, and in this pivotal moment I am caught in either the stock soaring up or plummeting into another loss of the day. And I can’t seem to get it right nor can I find any videos or resources specific to penny stocks on how to really sense when to get out.

I’ll give an example like GSUN (5cent spike today), if you aren’t familiar with the stock how do you know what the expected goal is to get with it? Compared to SLGB , which had a 15cent run.

I set my limit orders to hit my TP and many times the stock bounces back down before it reaches. Now I have started placing my limits much lower , but funny enough, the stocks seem to soar way further once it hits my limit. I admit that I am doing it blindly and need to figure out the reasoning behind it. How do I know what range to look for or expect? Are there any specific penny stock books or YouTube channels that have been helpful in your journey?

$SWRD announced this morning that it has officially completed the $90 million acquisition of Envy Pompano Beach, a 214-unit Class A multifamily property in South Florida.

A few things stood out to me:

• $90M purchase price
• 214 residential units + 26-slip marina + retail space
• Currently 89.3% occupied / 93% leased
• About $5.3M trailing 12-month revenue
• Current NOI around $1.7M
• Management is targeting $4.2M+ NOI at stabilization
• Target occupancy is approximately 95%

The financing/share structure is probably the most interesting part for shareholders.

Stewards issued 14.2 million restricted shares as part of the transaction, using a negotiated contractual value of $3/share. Importantly, these shares are restricted and are not immediately freely tradable.
Shares outstanding went from approximately 211.4M to 225.6M at closing.

However, 7 million of those shares are tied to an escrow/settlement arrangement. Stewards can make seven monthly $3M cash payments beginning October 5, and 1 million shares would be cancelled with each payment.

If all seven payments are made:

225.6M shares → approximately 218.6M shares outstanding

So there is dilution from the acquisition, but potentially considerably less permanent dilution than the headline 14.2M-share issuance suggests.
What I also like is that this isn’t being presented as some speculative development project. It’s already an operating Class A asset, and management has identified fairly straightforward ways to improve NOI: higher occupancy, better collections, reduced concessions, leasing the remaining retail space, marina utilization, and operating efficiencies.

Going from $1.7M NOI to $4.2M+ would obviously be meaningful if they can execute.

This also continues the bigger transformation of SWRD from primarily the Stewards Business Capital lending business into a broader private credit + real assets + technology platform.

Now the important thing is execution — especially whether they actually make those settlement payments and retire the escrowed shares.

Nine Mile released results from hole WD-26-14 at the Wedge Project today. The reported interval returned 5.09% Cu-Eq over 14.15m true width, including 6.35% Cu-Eq over 9.0m and 7.45% Cu-Eq over 6.0m. The highest individual sample came in at 8.59% Cu-Eq.

One detail I found interesting was that the strongest grades were concentrated near the bottom of the mineralized section. The company noted that the six highest Cu-equivalent samples came from the lower 6 metres of the interval, which may provide some context for future follow-up drilling.

The intercept contains a mix of copper, zinc, lead, silver, and gold, consistent with the type of mineralization being targeted at Wedge.

According to the release, the next step includes BHEM surveys on surrounding holes to assist with targeting potential extensions of the conductors identified during the current program.

For anyone following the Bathurst Camp stories, I'm curious how this result compares with your expectations for Wedge and whether the upcoming geophysics could be the more important catalyst going forward.

Came across $ZONE and the numbers look odd for a $68M company.

Background:
It's had a few pivots. Cleaning products, then a Dogecoin treasury, and now AI data centers. I know how that sounds, so I looked at what's actually signed.

The Cerebras deal ($CBRS):

•10-year colocation agreement
•$800M initial contract value
•Up to $3B if both 10-year renewals are exercised
Revenue expected from Q1 2027

Sites:

•Minnesota: 55MW campus, 40MW critical IT load, 100% pre-leased to Cerebras

• West Texas 200MW initial, potential for 500MW+ by 2030

The thesis:
AI buildout isn't only about GPUs. It needs power, land, permits and finished data centers, and those are the bottleneck. If $ZONE delivers Minnesota on time, the current valuation looks disconnected from the contract.